Believer Meats finished the checklist the cultivated-meat industry says is the barrier to market — safety clearance, production clearance, a built plant — faster and more completely than almost any company in the sector. Then it shut down anyway, six weeks after the last approval landed, with the equivalent of $86,000 in the bank.
That is not a company that failed to reach the regulatory finish line. It is a company that reached it and discovered the finish line was not the constraint.
The trifecta, completed in full
On 24 July 2025, Believer Meats (formerly Future Meat Technologies) announced it had received an FDA “no questions” letter — the fifth cultivated-meat company worldwide to clear the agency’s safety review — and had simultaneously completed construction of its production plant in Wilson County, North Carolina. CEO Gustavo Burger called it “the first and only large-scale cultivated meat production site in the world,” a claim Vow’s CEO George Peppou publicly disputed at the time, noting his own company had already produced at 20,000-litre scale for sale in Singapore and Australia.
On 31 October 2025, Believer cleared the second gate: a USDA grant of inspection and label sign-off, making it the fifth company allowed to sell cultivated meat in the US and the first non-US-founded startup to reach that milestone. “We are the first and only large-scale cultivated meat facility to have earned this approval from USDA,” Burger said in the announcement.
Both regulators had signed off. The plant existed — 200,000 square feet, with bioprocess partner GEA rating its annual capacity at roughly 12,000 metric tons of cultivated chicken. Believer held what one industry source told AgFunderNews was “the trifecta: FDA approval, USDA approval, and a full-size plant.”
Six weeks later, it was gone.
Timeline
| Date | Event |
|---|---|
| 24 Jul 2025 | FDA “no questions” letter secured; North Carolina plant construction completed |
| 31 Oct 2025 | USDA grant of inspection and label sign-off — commercial sale legally cleared |
| Oct 2025 | Gray Construction and Believer sign a forbearance agreement: $22m due by 5 Dec, remaining $12m in two 2026 instalments |
| 1 Dec 2025 | Mass layoffs begin at the North Carolina plant and executive level |
| 5 Dec 2025 | Believer misses the $22m forbearance deadline |
| 6 Dec 2025 | Gray Construction sues, alleging breach and seeking expedited foreclosure |
| 8 Dec 2025 | Case selected for mediation; AgFunderNews reports the lawsuit |
| 10–11 Dec 2025 | Shutdown announced via LinkedIn by HR lead Anne Schubert; company seeks a buyer |
| 31 Dec 2025 | Israeli parent files for insolvency protection; cash balance disclosed as $86k |
| 5 Jan 2026 | Lod District Court grants a 40-day stay; trustee Yoel Freilich appointed over Israeli entity and IP |
| 6 Feb 2026 | North Carolina court places the US subsidiary into general receivership under Kevin Sink |
| 9 Jun 2026 | UPSIDE Foods’ $50m stalking-horse bid approved as the sale baseline |
| 5 Aug 2026 | Extended deadline for competing bids on Believer’s IP portfolio (outcome not yet public) |
| 10 Aug 2026 | Extended deadline for competing bids on the North Carolina plant |
| 17 Aug 2026 | Auction for the plant, if a qualifying competing bid is submitted |
| 20 Aug 2026 | Sale hearing — the plant’s ownership is expected to be decided |
Practical consequence: the gap between “regulatory approval” and “viable” was not months. It was weeks, and the warning signs — a forbearance agreement, a missed staged payment — were visible in court filings before the public shutdown announcement. Anyone tracking a counterparty’s dependence on a single company should watch for restructured debt agreements, not just headline funding news.
The cash mechanics, not the science, killed it
The published account of what went wrong is thin — Believer’s leadership has never given a detailed public explanation — but the money trail is on the record in two separate court systems.
Gray Construction, which built the plant, says it was owed $36.4 million for design and construction work. After Believer fell behind on payment, Gray accepted a $25 million secured promissory note backed by a mortgage on the facility, then a forbearance agreement in October 2025 requiring $22 million by 5 December, with the remaining $12 million in two 2026 instalments. Believer missed the December deadline. Gray’s suit, filed 6 December in the US District Court for the Eastern District of North Carolina (case 5:25-cv-792), alleged the company had “materially breached the forbearance agreement… which constitutes a termination event,” and separately alleged Believer was insolvent under the terms of its loan agreements.
Three weeks later, Believer’s Israeli parent, Future Meat Technologies Ltd, filed for insolvency protection in the Lod District Court. That filing is the most concrete evidence available of how fast the position deteriorated: the company’s own cash balance on the filing date was ILS 270,455 — roughly $86,000 — against outstanding obligations to suppliers, employees and authorities. The filing states plainly that the company was “insolvent both on a cash-flow basis and on a balance-sheet basis.”
The same filing revised the plant’s cost upward: an initial estimate of $138 million grew to $154 million during construction — before the company disclosed that “attempts to raise additional financing in 2025 failed.” A marketing document later prepared for the asset sale puts the investment at “over $150 million,” consistent with the company’s own figure.
Two parallel insolvency processes are now unwinding the company: a US general receivership, opened 6 February 2026 with Kevin Sink liquidating the North Carolina plant and equipment for secured US creditors (Gray Construction and Ameris Bank, which is owed more than $13 million on a $25 million term loan, sit at the front of the queue), and a separate Israeli process in which trustee Yoel Freilich controls the company’s intellectual property. Neither can act on the other’s assets without consent — Sink has said he does not believe the Israeli entity owns anything at the North Carolina site, while Freilich has been explicit that “whoever purchases the plant in North Carolina does not get the IP or the know-how of the company… unless he buys it from” the Israeli entity.
Practical consequence: a fully permitted, fully built plant and its underlying process technology can end up in the hands of two different buyers, sold by two different courts, in two different countries. Anyone assessing counterparty risk in this sector should treat “who owns the IP” and “who owns the tanks” as separate questions with separate answers once a company is in distress.
What the wreckage is worth
The clearest number this story produces is not a projection — it is a live market price. On 9 June 2026, the North Carolina Business Court approved a $50 million stalking-horse bid from UPSIDE Foods, a direct competitor, for the Wilson County facility and its equipment: bioreactors, media and process tanks, centrifuges, freezing and wastewater systems, automation and process-control hardware, plus permits and licenses. A competing bid has to clear $52.25 million to be considered. The deadline for rival offers, originally 20 July, has since been pushed to 10 August, with an auction on 17 August and a sale hearing on 20 August if a qualifying bid arrives.
Set against the company’s own $150–154 million construction cost, a $50–52 million sale price is roughly a two-thirds discount to what it cost to build fifteen months earlier — the first real transaction-based data point this publication has found for what distressed, fully regulator-approved cultivated-meat manufacturing capacity is actually worth on resale, as opposed to what it costs to build new. That is a more useful number for anyone modelling scale-up economics than any techno-economic projection, because it is a price someone is actually willing to pay.
It would also be a significant capacity jump for the buyer. UPSIDE Foods, which has raised $608 million, paused its own large-scale plant in Glenview, Illinois in early 2024 and has since run pilot batches at roughly 2,000-litre scale at a smaller site in Emeryville, California. Believer’s bioreactors are understood to run at roughly 20,000 litres. UPSIDE told AgFunderNews the North Carolina facility “would accelerate the expansion of our production capacity and help us meet growing demand for UPSIDE chicken much sooner” — though the company has not said whether it would restart production at the scale Believer originally intended, or absorb the plant more cautiously, as it has with its own paused facility.
The IP is being sold separately and, by the trustee’s account, competitively: bids for cell lines, media formulations and scale-up know-how were due 5 August 2026, extended once already for “vast interest… from cultivated meat companies, investment funds, and other entities.” No outcome had been made public as of this writing.
The cost model was not the problem — the capital structure was
Believer’s own published research is the detail that sharpens this piece from a shutdown story into a scale-up story. In a peer-reviewed paper, the company reported an animal-free culture medium costing $0.63 per litre and a techno-economic model showing that, at a theoretical 50,000-litre production scale using perfusion technology, cultivated chicken could reach $6.20 per pound — within the range of retail organic chicken.
On paper, the unit economics looked like the industry’s stated goal: proof that cultivated protein could approach cost parity with conventional meat at scale. Believer built a plant to pursue exactly that model. It still ran out of cash before ever running production at the scale the model assumed.
This is the finding this publication has been circling since our review of the industry’s cost-data gap: a credible techno-economic pathway to lower cost is not the same claim as a company being able to survive the capital structure required to reach it. Believer’s facility cost overran by roughly 12% against its own initial estimate ($138 million to $154 million) during a year in which, by the company’s own admission, “attempts to raise additional financing… failed.” The gap between a defensible cost model and a fundable balance sheet is where this company died, not in the fermentation tanks.
Practical consequence: when evaluating a scale-up claim, the operative question is not “does the unit-economics model check out” but “does the company have committed capital to survive construction overruns and a slower-than-planned ramp.” Believer’s model may well have been right. It didn’t matter.
The counter-argument, stated properly
Several senior figures in the sector pushed back hard against reading Believer’s collapse as proof the category doesn’t work. Suzi Gerber, executive director of the Association for Meat, Poultry and Seafood Innovation, argued that “temporary setbacks, while unfortunate, do not represent the whole and thus should not overshadow the momentum” of a 2025 she called “a banner year” for regulatory approvals. Mosa Meat co-founder Mark Post argued a “shake-out… is a natural phase of maturation” and that his own company remains “laser-focused on the unit economics of scaling up” before committing to large capacity. Aleph Farms CEO Didier Toubia noted his company made the opposite bet after its own 2021 raise — pausing large capital expenditure in favour of an asset-light approach and a market sequence that doesn’t start in the US.
The harder critique came from outside the trifecta of approved companies. Redefine Meat founder Eshchar Ben-Shitrit argued the deeper issue predates Believer’s cash crunch: “the companies in the field produce cells, but producing cells is not producing meat. The cells do not contribute at all, at least not significantly, to taste or texture.” Clever Carnivore co-founder Paul Burridge was more pointed about the capital discipline question specifically: “with an unlimited budget, you can rush to hit certain milestones — like building a full-scale production facility — but you risk putting the cart before the horse… you can’t build an expensive biopharma-grade system to manufacture a commodity product.”
Both readings can be true at once. The regulatory and construction achievement was real. So was the mismatch between a commodity product’s margins and the capital intensity of the plant built to make it.
Not the only 2025 casualty
Believer is the largest and most-approved company to fail, but not the only one. UK-based CellRev and Dutch startup Upstream Foods both ceased operations in 2025; SCiFi Foods closed and released its cell lines to academia via GFI; Uncommon Bio sold its cultivated-meat platform to Meatable and pivoted to therapeutics. Consolidation moved the other direction for some: Orbillion Bio was acquired by Fork & Good, and Vital Meat was bought by Gourmey to form a new entity, Parima. Sector-wide, AgFunder’s tracked investment in cultivated meat fell from a $989 million peak in 2021 to $807 million (2022), $177 million (2023), $55 million (2024, excluding an undisclosed Hoxton Farms round) and $65 million in 2025. A fuller pattern analysis across these failures is a separate piece of work; this one is about what happened inside a single, unusually well-documented collapse.
What we could not establish
Believer’s total funding is reported inconsistently across sources. Calcalistech states “over $390 million,” Green Queen states “$387 million,” and AgFunderNews’s mid-2026 reporting rounds to “almost $400 million.” We have used “more than $390 million” as the figure best supported by the earliest, most detailed reporting, but could not reconcile the exact total.
A reported $213 million intercompany debt — the US subsidiary owing the Israeli parent — comes from Calcalist’s reporting of the bankruptcy filing, not from the filing text AgFunderNews itself reviewed, which did not contain that figure. We have not independently verified it and have left it out of the account above rather than repeat an unconfirmed number.
No company executive has given a detailed, on-the-record account of what specifically went wrong operationally. One anonymous source told AgFunderNews that staff had struggled to get hold of supplies needed to complete tasks at the plant in the months before the shutdown; this was not confirmed on the record and we treat it as unconfirmed.
The North Carolina facility’s rated capacity is reported as “roughly 12,000 metric tons” annually by GEA, AgFunderNews and Green Queen, but as “at least 10,000 tonnes” by MEAT+POULTRY. We used the more specific, repeated figure traceable to the bioprocess partner’s own statement.
The outcome of the 5 August 2026 IP-auction deadline was not public as of this writing.
What to watch
Does a competing bid clear $52.25 million by 10 August? If not, UPSIDE Foods’ $50 million baseline is likely to be confirmed at the 20 August sale hearing without a contest — a clean, dated test of whether any other buyer values this asset above the stalking-horse floor.
Does the plant and the IP end up with the same buyer, or two different ones? If UPSIDE wins the facility but not the process know-how, the practical value of the hardware — and how quickly any buyer can actually resume production — depends on an entirely separate transaction with a separate seller.
Does UPSIDE restart production at Wilson County, or mothball it as it did its own Glenview site? The company’s public comments have been about capacity expansion, not a committed timeline.
Where does full-year 2026 cultivated-meat funding land relative to 2025’s $65 million? Believer’s collapse removed the sector’s most visible capacity proof point at exactly the moment investors were already retreating.